Open AccessAdvantages and disadvantages of biodegradable platforms in drug eluting stents
Author(s) -
Agustina Rodriguez-Granillo,
Bibiana Rubilar,
Gastón A. Rodríguez-Granillo,
Alfredo E. Rodríguez
Publication year - 2011
Publication title -
world journal of cardiology
Language(s) - English
Resource type - Journals
ISSN - 1949-8462
DOI - 10.4330/wjc.v3.i3.84
Subject(s) - medicine , restenosis , stent , drug eluting stent , target lesion , randomized controlled trial , drug , sirolimus , thrombosis , biodegradable polymer , surgery , myocardial infarction , pharmacology , percutaneous coronary intervention , polymer , chemistry , organic chemistry
Coronary angioplasty with drug-eluting stent (DES) implantation is currently the most common stent procedure worldwide. Since the introduction of DES, coronary restenosis as well as the incidence of target vessel and target lesion revascularization have been significantly reduced. However, the incidence of very late stent thrombosis beyond the first year after stent deployment has more commonly been linked to DES than to bare-metal stent (BMS) implantation. Several factors have been associated with very late stent thrombosis after DES implantation, such as delayed healing, inflammation, stent mal-apposition and endothelial dysfunction. Some of these adverse events were associated with the presence of durable polymers, which were essential to allow the elution of the immunosuppressive drug in the first DES designs. The introduction of erodable polymers in DES technology has provided the potential to complete the degradation of the polymer simultaneously or immediately after the release of the immunosuppressive drug, after which a BMS remains in place. Several DES designs with biodegradable (BIO) polymers have been introduced in preclinical and clinical studies, including randomized trials. In this review, we analyze the clinical results from 6 observational and randomized studies with BIO polymers and discuss advantages and disadvantages of this new technology.